Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
HRT Shows No Adverse Effect on Breast Cancer Risk in Patients With BRCA Variant
2
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
3
Imlunestrant Regimens Sustain Efficacy Benefit in ER+/HER2– Breast Cancer
4
Sacituzumab Govitecan/Pembrolizumab Offers Manageable, Predictable Safety Profile in TNBC
5
